Suplemento II · Revista nº 814

37 Suárez Arana M, et al. | COVID-19 y embarazo Actual Med. 2021; 106(814). Supl2: 27- 38 S U P L E M E N T O C O V I D - 1 9 12. Groß R, Conzelmann C, Müller JA, Stenger S, Steinhart K, Kirchhoff F, et al. Detection of SARS-CoV-2 in human breastmilk. Lancet. (2020) 395:1757–8. doi: 10.1016/ S0140-6736(20)31181-8 13. Costa S, Posteraro B, Marchetti S, Tamburrini E, Carduc- ci B, Lanzone A, et al. Excretion of SARS-CoV-2 in human breast milk. Clin Microbiol Infect. (2020) 26:1430–2. doi: 10.1016/j.cmi.2020.05.027 14. Tam PCK, Ly KM, Kernich ML, Spurrier N, Lawrence D, Gor- don DL, et al. Detectable severe acute respiratory syndro- me coronavirus 2 (SARS-CoV-2) in human breast milk of a mildly symptomatic patient with coronavirus disease 2019 (COVID-19). Clin Infect Dis. (2020). doi: 10.1093/cid/ ciaa673. 15. Chambers C, Krogstad P, Bertrand K, Contreras D, Tobin NH, Bode L, et al. Evaluation for SARS-CoV-2 in breast milk from 18 infected women. JAMA. (2020) 324:1347–8. doi: 10.1001/jama.2020.15580 16. Bertino E, Moro GE, De Renzi G, Viberti G, Cavallo R, Coscia A, et al. SARS-CoV-2 in human breast milk and neonatal outcome: a collaborative study. SSRN Electron J. (2020). doi: 10.2139/ssrn.3611974.  17. Bastug A, Hanifehnezhad A, Tayman C, Ozkul A, Ozbay O, Kazancioglu S, et al. Virolactia in an asymptomatic mother with COVID-19. Breastfeed Med. (2020) 15:488–91. doi: 10.1089/bfm.2020.0161 18. Mitoulas LR, Schärer-Hernández NG and Liabat S (2020) Breastfeeding, Human Milk and COVID-19. What Does the Evidence Say? Front. Pediatr. 8:613339. doi: 10.3389/ fped.2020.613339 19. Cheema R, Partridge E, Kair LR, Kuhn-Riordon KM, Silva AI, Bettinelli ME, et al. Protecting breastfeeding during the COVID-19 pandemic. Am J Perinatol. (2020). doi: 10.1055/ s-0040-1714277. 20. Cruz Melguizo S, De la Cruz Conty ML, Carmona P, Abascal –Saiz A, Pintado P, González Rodriguez L, Cuenca Marín C, Martinez Varea A, Oreja AB el at. Pregnancy Outcomes and SARS-CoV-2 Infection: The Spanish Obstetric Emergency Group Study. Viruses 2021,13,853. Doi: 10.3390/v13050853. 21. Documentos técnicos del Ministerio de Sanidad: https:// www.mscbs.gob.es/profesionales/saludPublica 22. Tavazzi G, Civardi L, Caneva L, Mongodi S, Mojoli F. Throm- botic events in SARS-CoV-2 patients: an urgent call for ul- trasound screening. Intensive Care Med 2020) 23. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. First publi- shed 25 March 2020; https://doi.org/10.1111/jth.14810 ; 24. Thrombosis UK. Practical guidance for the prevention of thrombosis and management of coagulopathy and dis- seminated intravascular coagulation of patients infected with COVID-19 [Internet]. Disponible en: https://thrombo- sisuk.org/covid-19-thrombosis.php 25. Sociedad Española de Trombosis y Hemostasia (SETH). Recomendaciones de tromboprofilaxis y tratamien- to antitrombótico en pacientes con COVID-19 [con- sultado 10 de agosto de 2020]. Disponible en: https:// www.covid-19.seth.es/recomendaciones-de-trom- boprofilaxis-y-tratamiento-antitrombotico-en-pacien- tes-con-covid-19/. 26. Llover, M. N., & Jiménez, M. C. (2021). Estado actual de los tratamientos para la COVID-19. FMC : Formación medica continuada en atención primaria, 28(1), 40–56. https:// doi.org/10.1016/j.fmc.2020.10.005 27. AEMPS. Tratamientos disponibles sujetos a condicio- nes especiales de acceso para el manejo de la infec- ción respiratoria por SARS-CoV-2.Disponible en: ht- tps://www.aemps.gob.es/la-aemps/ultima-informa- cion-de-la-aemps-acerca-del-covid %e2%80%9119/ tratamientos-disponibles-para-el-manejo-de-la- infec- cion-respiratoria-por-sars-cov-2/?lang = en. 28. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Re- sults. NEJM.Disponible en: https://www.nejm.org/doi/ full/10.1056/NEJMoa2023184 29. Remdesivir for COVID-19. Aust Prescr [consultado 20 de agosto de 2020]. Disponible en: https://www.nps.org.au/ australian-prescriber/articles/remdesivir-for-covid-19. 30. Rosas IO, Bräu N, Waters M, Go R, Hunter BH, Bhagani S, et al. Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia. Preprint [consultado 18 de septiembre de 2020]. Disponible en: https://www.medrxiv.org/content/1 0.1101/2020.08.27.20183442v2. 31. FDA. Coronavirus (COVID-19) Update: FDA Revokes Emer- gency Use Authorization for Chloroquine and Hydroxy- chloroquine. June 15, 2020 [consultado 9 de julio de 2020]. Disponible en: https://www.fda.gov/news-events/ press-announcements/coronavirus-covid-19-upda- te-fda-revokes-emergency-use-authorization-chloroqui- ne-and. 32. Horby P., Lim W.S., Emberson J., Mafham M., Bell J., Lin- sell L. RECOVERY Collaborative Group Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Re- port. NEJM. 2020 DOI: 10.1056/NEJMoa2021436 [con- sultado 8 de septiembre de 2020]. Disponible en: https:// www.nejm.org/doi/full/10.1056/NEJMoa 2021436#arti- cle_references. 33. The WHO evidence appraisal for COVID-19 therapies (RE- ACT) working group Association between administration of systemic corticoids and mortality among critically ill patients with COVID-19. A meta-analysis. JAMA. 2020. Disponible en: https://jamanetwork.com/journals/jama/ fullarticle/2770279